CA3071315A1 - Dual mode radiotracer and -therapeutics - Google Patents
Dual mode radiotracer and -therapeutics Download PDFInfo
- Publication number
- CA3071315A1 CA3071315A1 CA3071315A CA3071315A CA3071315A1 CA 3071315 A1 CA3071315 A1 CA 3071315A1 CA 3071315 A CA3071315 A CA 3071315A CA 3071315 A CA3071315 A CA 3071315A CA 3071315 A1 CA3071315 A1 CA 3071315A1
- Authority
- CA
- Canada
- Prior art keywords
- bond
- oligo
- conjugate
- acid
- amide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Nuclear Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17183795.8 | 2017-07-28 | ||
| EP17183795 | 2017-07-28 | ||
| PCT/EP2018/070533 WO2019020831A1 (en) | 2017-07-28 | 2018-07-30 | AGENTS WITH TWO RADIOTRATIVE AND THERAPEUTIC MODES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3071315A1 true CA3071315A1 (en) | 2019-01-31 |
Family
ID=59501286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3071315A Pending CA3071315A1 (en) | 2017-07-28 | 2018-07-30 | Dual mode radiotracer and -therapeutics |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US11413360B2 (enExample) |
| EP (3) | EP4424378A3 (enExample) |
| JP (2) | JP7059372B2 (enExample) |
| KR (2) | KR20240027896A (enExample) |
| CN (1) | CN111132700B (enExample) |
| AU (2) | AU2018308699B2 (enExample) |
| BR (1) | BR112020001785A2 (enExample) |
| CA (1) | CA3071315A1 (enExample) |
| DK (1) | DK3658194T3 (enExample) |
| EA (1) | EA202090370A1 (enExample) |
| ES (1) | ES3011272T3 (enExample) |
| FI (1) | FI3658194T3 (enExample) |
| HU (1) | HUE070098T2 (enExample) |
| IL (2) | IL272291B2 (enExample) |
| MX (2) | MX2020000352A (enExample) |
| PL (1) | PL3658194T3 (enExample) |
| PT (1) | PT3658194T (enExample) |
| SG (1) | SG11202000725WA (enExample) |
| WO (1) | WO2019020831A1 (enExample) |
| ZA (1) | ZA202000467B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240027896A (ko) | 2017-07-28 | 2024-03-04 | 테크니쉐 우니베르지테트 뮌헨 | 이중 모드 방사성 트레이서 및 치료법 |
| BR112021012110A2 (pt) * | 2019-01-30 | 2021-09-08 | Technische Universität München | Radiofarmacêuticos substituídos por aceptor de fluoreto de silício |
| WO2020157177A1 (en) * | 2019-01-30 | 2020-08-06 | Technische Universität München | Psma binding dual mode radiotracer and therapeutic |
| CA3128406A1 (en) * | 2019-01-30 | 2020-08-06 | Technische Universitat Munchen | Cancer diagnostic imaging agents |
| CN112168978B (zh) * | 2019-07-03 | 2022-01-11 | 北京大学 | 一种抗体偶联药物及其药物组合物与应用 |
| EP4041213A4 (en) * | 2019-10-29 | 2023-12-27 | The Cleveland Clinic Foundation | Psma-targeting imaging agents |
| CN113350531A (zh) * | 2020-03-02 | 2021-09-07 | 上海核力星医药科技有限公司 | 前列腺特异性膜抗原结合配体偶联物及其应用 |
| GB202005282D0 (en) * | 2020-04-09 | 2020-05-27 | Blue Earth Diagnostics Ltd | Pharmaceutical Formulations |
| EP4185336A1 (en) | 2020-07-23 | 2023-05-31 | Technische Universität München | Silicon-containing ligand compounds |
| KR20230066382A (ko) | 2020-09-03 | 2023-05-15 | 큐리엄 유에스 엘엘씨 | 64Cu-DOTATATE의 스케일 업을 위한 방사성표지 및 제형 |
| EP4023250A1 (en) * | 2021-01-04 | 2022-07-06 | Technische Universität München | Dual mode radiotracer and -therapeutics |
| IL305134A (en) * | 2021-02-15 | 2023-10-01 | Technische Universit?T M?Nchen | Dual mode radio and medical tracker |
| CA3215723A1 (en) * | 2021-04-02 | 2022-10-06 | Advanced Accelerator Applications | Diagnostic methods of prostate cancer |
| JP2024517971A (ja) * | 2021-05-14 | 2024-04-23 | テクニシェ ユニバーシタット ミュンヘン | 放射性医薬品のソマトスタチン受容体リガンドおよびその前駆体 |
| GB202108779D0 (en) | 2021-06-18 | 2021-08-04 | Blue Earth Diagnostics Ltd | Si-at therapeutic/diagnostic compounds |
| GB202109922D0 (en) | 2021-07-09 | 2021-08-25 | Blue Earth Diagnostics Ltd | Radiotracers and therapeutics binding to fibroblast activation protein (fap) |
| US20250313579A1 (en) * | 2021-08-05 | 2025-10-09 | Technische Universität München | Ligand compounds comprising a chelating group as a bridging group |
| GB202113646D0 (en) | 2021-09-24 | 2021-11-10 | Blue Earth Diagnostics Ltd | Method of preparation of 18F labelled silyl-fluoride compounds |
| CN114671806B (zh) * | 2022-04-08 | 2024-03-01 | 上海如絮生物科技有限公司 | 一种亲水性吡啶衍生物、中间体、其制备方法及应用 |
| GB202207372D0 (en) | 2022-05-19 | 2022-07-06 | Blue Earth Diagnostics Ltd | Synthesis of fluorosilyl compounds |
| JP2025525111A (ja) | 2022-07-29 | 2025-08-01 | テクニシェ ユニバーシタット ミュンヘン | 放射性医薬品のためのケイ素系フッ化物アクセプター基 |
| WO2024054226A1 (en) * | 2022-09-06 | 2024-03-14 | Hoang Ba Xuan | Gallium nitrate and dimethyl sulfoxide composition for respiratory treatment |
| CA3264385A1 (en) * | 2022-09-20 | 2024-03-28 | Universität Augsburg | NEW MINIGASTRINE-DERIVED CHOLECYSTOKIN 2 RECEPTOR-BINDING MOLECULES FOR TARGETED IMAGING AND RADIOTHERAPY |
| TW202426433A (zh) | 2022-09-23 | 2024-07-01 | 瑞士商紐利迪姆股份公司 | 成纖維細胞活化蛋白（ｆａｐ）抑制劑、ｆａｐ結合物及其診斷與治療用途 |
| IL319722A (en) | 2022-09-23 | 2025-05-01 | Nuclidium Ag | High purity radionuclides and their diagnostic and medical uses |
| CN120417945A (zh) * | 2022-11-14 | 2025-08-01 | 阿克提斯肿瘤学公司 | 肾脏中小蛋白滞留的减少 |
| KR20260085122A (ko) | 2023-09-29 | 2026-06-08 | 악티스 온콜로지, 인크. | 미니단백질, 접합체 및 이의 용도 |
| GB202316239D0 (en) | 2023-10-24 | 2023-12-06 | Blue Earth Diagnostics Ltd | Therapeutic combination |
| WO2025250644A1 (en) * | 2024-05-28 | 2025-12-04 | Case Western Reserve University | Fluorescent nuclide-containing agents for detecting and treating cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7384394A (en) * | 1993-06-30 | 1995-01-24 | Akzo Nobel N.V. | Chelating compounds |
| EP1420831A1 (en) * | 2001-07-27 | 2004-05-26 | Targesome, Inc. | Lipid constructs as therapeutic and imaging agents |
| CN102626522B (zh) * | 2012-04-12 | 2014-09-10 | 韩彦江 | 基于趋化因子受体cxcr4多肽类拮抗剂的多肽放射性诊断与治疗药物 |
| CA2949936C (en) * | 2014-06-10 | 2022-10-18 | 3B Pharmaceuticals Gmbh | Conjugate comprising a neurotensin receptor ligand and use thereof |
| EP3209336B1 (en) | 2014-10-20 | 2019-12-11 | Deutsches Krebsforschungszentrum | 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| US20160287730A1 (en) * | 2015-03-31 | 2016-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Labeled evans blue dye derivative for in vivo serum albumin labeling |
| EP3303349B1 (en) * | 2015-05-26 | 2022-07-06 | The Regents of the University of California | Novel heteroaromatic silicon-fluoride-acceptors useful for 18f labeling of molecules and biomolecules, and methods of preparing same |
| KR20240027896A (ko) | 2017-07-28 | 2024-03-04 | 테크니쉐 우니베르지테트 뮌헨 | 이중 모드 방사성 트레이서 및 치료법 |
| DK3723815T3 (da) * | 2017-12-11 | 2022-07-11 | Univ Muenchen Tech | PSMA ligander til billeddannelse og endoradioterapi |
| CA3128406A1 (en) | 2019-01-30 | 2020-08-06 | Technische Universitat Munchen | Cancer diagnostic imaging agents |
| WO2020157177A1 (en) | 2019-01-30 | 2020-08-06 | Technische Universität München | Psma binding dual mode radiotracer and therapeutic |
-
2018
- 2018-07-30 KR KR1020247006169A patent/KR20240027896A/ko active Pending
- 2018-07-30 IL IL272291A patent/IL272291B2/en unknown
- 2018-07-30 CA CA3071315A patent/CA3071315A1/en active Pending
- 2018-07-30 SG SG11202000725WA patent/SG11202000725WA/en unknown
- 2018-07-30 AU AU2018308699A patent/AU2018308699B2/en active Active
- 2018-07-30 US US16/634,759 patent/US11413360B2/en active Active
- 2018-07-30 PT PT187435409T patent/PT3658194T/pt unknown
- 2018-07-30 BR BR112020001785-0A patent/BR112020001785A2/pt unknown
- 2018-07-30 MX MX2020000352A patent/MX2020000352A/es unknown
- 2018-07-30 ES ES18743540T patent/ES3011272T3/es active Active
- 2018-07-30 CN CN201880062949.0A patent/CN111132700B/zh active Active
- 2018-07-30 DK DK18743540.9T patent/DK3658194T3/da active
- 2018-07-30 FI FIEP18743540.9T patent/FI3658194T3/fi active
- 2018-07-30 IL IL318092A patent/IL318092A/en unknown
- 2018-07-30 HU HUE18743540A patent/HUE070098T2/hu unknown
- 2018-07-30 KR KR1020207005589A patent/KR102752620B1/ko active Active
- 2018-07-30 EP EP24184312.7A patent/EP4424378A3/en active Pending
- 2018-07-30 EP EP18743540.9A patent/EP3658194B1/en active Active
- 2018-07-30 PL PL18743540.9T patent/PL3658194T3/pl unknown
- 2018-07-30 JP JP2020526688A patent/JP7059372B2/ja active Active
- 2018-07-30 EA EA202090370A patent/EA202090370A1/ru unknown
- 2018-07-30 WO PCT/EP2018/070533 patent/WO2019020831A1/en not_active Ceased
- 2018-07-30 EP EP22150556.3A patent/EP4000640A1/en not_active Withdrawn
-
2020
- 2020-01-10 MX MX2023007914A patent/MX2023007914A/es unknown
- 2020-01-23 ZA ZA2020/00467A patent/ZA202000467B/en unknown
-
2022
- 2022-04-12 JP JP2022065524A patent/JP2022101601A/ja active Pending
- 2022-06-24 US US17/849,297 patent/US12390540B2/en active Active
-
2024
- 2024-01-24 AU AU2024200440A patent/AU2024200440B2/en active Active
- 2024-11-15 US US18/948,808 patent/US12453787B2/en active Active
-
2025
- 2025-09-24 US US19/338,850 patent/US20260021211A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2024200440B2 (en) | Dual mode radiotracer and -therapeutics | |
| JP7393485B2 (ja) | 前立腺特異的膜抗原（ｐｓｍａ）の標識インヒビター、前立腺癌の治療のための画像化剤および薬剤としてのその使用 | |
| CN113573743B (zh) | 癌症诊断成像剂 | |
| CN113677400B (zh) | 结合psma的双模式放射性示踪剂及治疗剂 | |
| CA3179555A1 (en) | Pharmaceutical formulations | |
| KR20230160806A (ko) | 이중 모드 방사성 트레이서 및 치료법 | |
| WO2022018264A1 (en) | Silicon-containing ligand compounds | |
| HK40022705B (en) | Dual mode radiotracer and -therapeutics | |
| HK40022705A (en) | Dual mode radiotracer and -therapeutics | |
| EA046402B1 (ru) | Двухрежимная радиоактивная метка и радиотерапевтическое средство | |
| EA052134B1 (ru) | Двухрежимная радиоактивная метка и радиотерапевтическое средство |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230614 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240729 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240729 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240729 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20240813 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241212 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250206 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250612 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250612 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250725 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250725 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260408 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260408 |